Further pharmacological validation of the BALB/c neophobia in the free exploratory paradigm as an animal model of trait anxiety. Belzung, C. & Berton, F. Behavioural Pharmacology, 8(6-7):541--548, November, 1997. abstract bibtex The present experiments were aimed at investigating the ability of established or putative anxiolytics to reduce the neophobia exhibited by BALB/c mice in the free exploratory paradigm. Results confirm the anxiolytic effects of the benzodiazepine receptor full agonist chlordiazepoxide (2.5-7.5 mg/kg), of meprobamate (15-60 mg/kg) and of ethanol (0.5-1.5 g/kg) and extend the pharmacological action of these compounds to a test situation devoid of anxiogenic components, that is to trait anxiety. The non-competitive NMDA antagonist MK 801 (0.04-0.16 mg/kg) elicited very similar behavioural effects. However, the alpha 2-adrenoceptor antagonists yohimbine (0.5-2 mg/kg) and idazoxan (0.3-2.7 mg/kg), the barbiturate pentobarbital (3.75-30 mg/kg), the mixed 5HT2 receptor antagonist ritanserin (0.25-4 mg/kg) and the D2 dopaminergic antagonist sulpiride (8-32 mg/kg) failed to decrease neophobia in BALB/c mice. The discussion focuses on the adequacy of this animal model of human pathology. The BALB/c neophobia may not model panic attacks because of the absence of worsening by the panic-provoking agent yohimbine and the lack of attenuation by CCK-B receptor antagonists. Because of its chronicity, this paradigm may model generalized anxiety, a pathology that has been suggested to overlap trait anxiety.
@article{ belzung_further_1997,
title = {Further pharmacological validation of the {BALB}/c neophobia in the free exploratory paradigm as an animal model of trait anxiety},
volume = {8},
issn = {0955-8810},
abstract = {The present experiments were aimed at investigating the ability of established or putative anxiolytics to reduce the neophobia exhibited by {BALB}/c mice in the free exploratory paradigm. Results confirm the anxiolytic effects of the benzodiazepine receptor full agonist chlordiazepoxide (2.5-7.5 mg/kg), of meprobamate (15-60 mg/kg) and of ethanol (0.5-1.5 g/kg) and extend the pharmacological action of these compounds to a test situation devoid of anxiogenic components, that is to trait anxiety. The non-competitive {NMDA} antagonist {MK} 801 (0.04-0.16 mg/kg) elicited very similar behavioural effects. However, the alpha 2-adrenoceptor antagonists yohimbine (0.5-2 mg/kg) and idazoxan (0.3-2.7 mg/kg), the barbiturate pentobarbital (3.75-30 mg/kg), the mixed 5HT2 receptor antagonist ritanserin (0.25-4 mg/kg) and the D2 dopaminergic antagonist sulpiride (8-32 mg/kg) failed to decrease neophobia in {BALB}/c mice. The discussion focuses on the adequacy of this animal model of human pathology. The {BALB}/c neophobia may not model panic attacks because of the absence of worsening by the panic-provoking agent yohimbine and the lack of attenuation by {CCK}-B receptor antagonists. Because of its chronicity, this paradigm may model generalized anxiety, a pathology that has been suggested to overlap trait anxiety.},
language = {eng},
number = {6-7},
journal = {Behavioural Pharmacology},
author = {Belzung, C. and Berton, F.},
month = {November},
year = {1997},
pmid = {9832968},
keywords = {Animals, Anti-Anxiety Agents, Anxiety, Behavior, Animal, Disease Models, Animal, Dose-Response Relationship, Drug, Exploratory Behavior, Male, Mice, Mice, Inbred {BALB} C, Motor Activity},
pages = {541--548}
}
Downloads: 0
{"_id":"y24G9KoBezDESXQc6","authorIDs":[],"author_short":["Belzung, C.","Berton, F."],"bibbaseid":"belzung-berton-furtherpharmacologicalvalidationofthebalbcneophobiainthefreeexploratoryparadigmasananimalmodeloftraitanxiety-1997","bibdata":{"abstract":"The present experiments were aimed at investigating the ability of established or putative anxiolytics to reduce the neophobia exhibited by BALB/c mice in the free exploratory paradigm. Results confirm the anxiolytic effects of the benzodiazepine receptor full agonist chlordiazepoxide (2.5-7.5 mg/kg), of meprobamate (15-60 mg/kg) and of ethanol (0.5-1.5 g/kg) and extend the pharmacological action of these compounds to a test situation devoid of anxiogenic components, that is to trait anxiety. The non-competitive NMDA antagonist MK 801 (0.04-0.16 mg/kg) elicited very similar behavioural effects. However, the alpha 2-adrenoceptor antagonists yohimbine (0.5-2 mg/kg) and idazoxan (0.3-2.7 mg/kg), the barbiturate pentobarbital (3.75-30 mg/kg), the mixed 5HT2 receptor antagonist ritanserin (0.25-4 mg/kg) and the D2 dopaminergic antagonist sulpiride (8-32 mg/kg) failed to decrease neophobia in BALB/c mice. The discussion focuses on the adequacy of this animal model of human pathology. The BALB/c neophobia may not model panic attacks because of the absence of worsening by the panic-provoking agent yohimbine and the lack of attenuation by CCK-B receptor antagonists. Because of its chronicity, this paradigm may model generalized anxiety, a pathology that has been suggested to overlap trait anxiety.","author":["Belzung, C.","Berton, F."],"author_short":["Belzung, C.","Berton, F."],"bibtex":"@article{ belzung_further_1997,\n title = {Further pharmacological validation of the {BALB}/c neophobia in the free exploratory paradigm as an animal model of trait anxiety},\n volume = {8},\n issn = {0955-8810},\n abstract = {The present experiments were aimed at investigating the ability of established or putative anxiolytics to reduce the neophobia exhibited by {BALB}/c mice in the free exploratory paradigm. Results confirm the anxiolytic effects of the benzodiazepine receptor full agonist chlordiazepoxide (2.5-7.5 mg/kg), of meprobamate (15-60 mg/kg) and of ethanol (0.5-1.5 g/kg) and extend the pharmacological action of these compounds to a test situation devoid of anxiogenic components, that is to trait anxiety. The non-competitive {NMDA} antagonist {MK} 801 (0.04-0.16 mg/kg) elicited very similar behavioural effects. However, the alpha 2-adrenoceptor antagonists yohimbine (0.5-2 mg/kg) and idazoxan (0.3-2.7 mg/kg), the barbiturate pentobarbital (3.75-30 mg/kg), the mixed 5HT2 receptor antagonist ritanserin (0.25-4 mg/kg) and the D2 dopaminergic antagonist sulpiride (8-32 mg/kg) failed to decrease neophobia in {BALB}/c mice. The discussion focuses on the adequacy of this animal model of human pathology. The {BALB}/c neophobia may not model panic attacks because of the absence of worsening by the panic-provoking agent yohimbine and the lack of attenuation by {CCK}-B receptor antagonists. Because of its chronicity, this paradigm may model generalized anxiety, a pathology that has been suggested to overlap trait anxiety.},\n language = {eng},\n number = {6-7},\n journal = {Behavioural Pharmacology},\n author = {Belzung, C. and Berton, F.},\n month = {November},\n year = {1997},\n pmid = {9832968},\n keywords = {Animals, Anti-Anxiety Agents, Anxiety, Behavior, Animal, Disease Models, Animal, Dose-Response Relationship, Drug, Exploratory Behavior, Male, Mice, Mice, Inbred {BALB} C, Motor Activity},\n pages = {541--548}\n}","bibtype":"article","id":"belzung_further_1997","issn":"0955-8810","journal":"Behavioural Pharmacology","key":"belzung_further_1997","keywords":"Animals, Anti-Anxiety Agents, Anxiety, Behavior, Animal, Disease Models, Animal, Dose-Response Relationship, Drug, Exploratory Behavior, Male, Mice, Mice, Inbred BALB C, Motor Activity","language":"eng","month":"November","number":"6-7","pages":"541--548","pmid":"9832968","title":"Further pharmacological validation of the BALB/c neophobia in the free exploratory paradigm as an animal model of trait anxiety","type":"article","volume":"8","year":"1997","bibbaseid":"belzung-berton-furtherpharmacologicalvalidationofthebalbcneophobiainthefreeexploratoryparadigmasananimalmodeloftraitanxiety-1997","role":"author","urls":{},"keyword":["Animals","Anti-Anxiety Agents","Anxiety","Behavior","Animal","Disease Models","Animal","Dose-Response Relationship","Drug","Exploratory Behavior","Male","Mice","Mice","Inbred BALB C","Motor Activity"],"downloads":0},"bibtype":"article","biburl":"https://api.zotero.org/users/1159944/collections/E8WPEHKT/items?key=urSIQu4xIZyj2vzMTXEsCcOu&format=bibtex&limit=100","creationDate":"2015-02-11T08:35:09.962Z","downloads":0,"keywords":["animals","anti-anxiety agents","anxiety","behavior","animal","disease models","animal","dose-response relationship","drug","exploratory behavior","male","mice","mice","inbred balb c","motor activity"],"search_terms":["further","pharmacological","validation","balb","neophobia","free","exploratory","paradigm","animal","model","trait","anxiety","belzung","berton"],"title":"Further pharmacological validation of the BALB/c neophobia in the free exploratory paradigm as an animal model of trait anxiety","year":1997,"dataSources":["dmyFHrN3jfT2RKa7k"]}